Enterprise Value
219.1M
Cash
104.1M
Avg Qtr Burn
-16.16M
Short % of Float
6.98%
Insider Ownership
10.07%
Institutional Own.
54.69%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PRGN-2009 OTS AdenoVerse Details Cancer, Solid tumor/s | Phase 2 Interim update | |
PRGN-2009 Comb w/ pembrolizumab Details Cancer, Cervical cancer | Phase 2 Initiation | |
PRGN-2012 AdenoVerse™ Details Recurrent respiratory papillomatosis | Phase 1/2 Update | |
AG019 ActoBiotics™ Details Type 1 Diabetes | Phase 1/2 Update | |
PRGN-3005 UltraCAR-T® Details Ovarian cancer, Cancer | Phase 1b Data readout | |
PRGN-3006 UltraCAR-T® Details Cancer, Myelodysplastic syndrome, Acute myeloid leukemia | Phase 1b Data readout | |
PRGN-3007 UltraCAR-T® Details Cancer, Solid tumor/s, Blood cancer | Phase 1 Data readout |